A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease.

Gastroenterol Res Pract

Department of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.

Published: October 2017

Purpose: This study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn's disease (CD).

Methods: A computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performed. Randomized controlled trials (rcts) or nonrandomized controlled trials (n-rcts) were included in this article to evaluate the role of ADA in the management of fistula in CD. The methodological index for nonrandomized studies (MINORS evaluation tools) was used to assess the quality of every study.

Result: Overall, seven studies and 379 patients comforted to the inclusion criteria of this meta-analysis. The result showed that 36% (95% CI: 0.31-0.41) of patients with complete fistula closure and 31% (95% CI: 0.031-0.61) of patients with partial response were received in CD with ADA treatment.

Conclusion: We concluded that ADA is effective and safe for the treatment of fistula in CD according to current evidence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674503PMC
http://dx.doi.org/10.1155/2017/1745692DOI Listing

Publication Analysis

Top Keywords

fistula crohn's
8
crohn's disease
8
controlled trials
8
fistula
5
meta-analysis adalimumab
4
adalimumab fistula
4
disease purpose
4
purpose study
4
study aimed
4
aimed evaluate
4

Similar Publications

This case report describes Crohn's disease complicated by squamous cell carcinoma in an enterocutaneous fistula. A 48-year-old male patient was diagnosed with Crohn's disease 24 years ago and has undergone five surgical operations. An enterocutaneous fistula originated from the midline abdominal wound 11 years after the onset.

View Article and Find Full Text PDF

Injectable DAT-ALG Hydrogel Mitigates Senescence of Loaded DPMSCs and Boosts Healing of Perianal Fistulas in Crohn's Disease.

ACS Biomater Sci Eng

January 2025

Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China.

Perianal fistulas (PAFs) are a severe complication of Crohn's disease that significantly impact patient prognosis and quality of life. While stem-cell-based strategies have been widely applied for PAF treatment, their efficacy remains limited. Our study introduces an injectable, temperature-controlled decellularized adipose tissue-alginate hydrogel loaded with dental pulp mesenchymal stem cells (DPMSCs) for in vivo fistula treatment.

View Article and Find Full Text PDF

Introduction: Crohn's disease is a chronic, complex inflammatory disorder of the gastrointestinal tract. Among its most challenging complications are perianal fistulas.

Aim: This study aims to explore the efficacy of hyperbaric oxygen therapy (HBOT) in reducing the activity of perianal fistulas in Crohn's disease patients.

View Article and Find Full Text PDF

A 23-year-old man was diagnosed with Crohn's disease (CD) of the large intestine after colonoscopy revealed longitudinal ulcers, and pathology revealed non-caseating epithelioid cell granulomas and anal fistulas. The CD relapsed, and therefore prednisolone (PSL) and infliximab (IFX) treatment was initiated. The PSL was gradually tapered.

View Article and Find Full Text PDF

BACKGROUND Crohn disease is a chronic inflammatory bowel disease known for causing fistulous tracts, abscesses, and bowel perforation. Enterohepatic fistulas, a rare but significant complication, are scarcely reported. This article presents the case of a hepatic abscess due to an enterohepatic fistula in a patient with long-term Crohn disease and reviews the existing literature on this phenomenon.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!